Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $15.5 million.

  • Allogene Therapeutics' Other Non-Current Liabilities rose 10186.54% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 10186.54%. This contributed to the annual value of $7.8 million for FY2024, which is 4985.52% up from last year.
  • Latest data reveals that Allogene Therapeutics reported Other Non-Current Liabilities of $15.5 million as of Q3 2025, which was up 10186.54% from $15.1 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Other Non-Current Liabilities peaked at $15.5 million during Q3 2025, and registered a low of $2.8 million during Q1 2021.
  • In the last 5 years, Allogene Therapeutics' Other Non-Current Liabilities had a median value of $6.3 million in 2022 and averaged $7.3 million.
  • Per our database at Business Quant, Allogene Therapeutics' Other Non-Current Liabilities surged by 15693.3% in 2022 and then tumbled by 2741.6% in 2023.
  • Over the past 5 years, Allogene Therapeutics' Other Non-Current Liabilities (Quarter) stood at $7.8 million in 2021, then decreased by 24.96% to $5.8 million in 2022, then dropped by 11.42% to $5.2 million in 2023, then skyrocketed by 49.86% to $7.8 million in 2024, then skyrocketed by 99.39% to $15.5 million in 2025.
  • Its last three reported values are $15.5 million in Q3 2025, $15.1 million for Q2 2025, and $11.3 million during Q1 2025.